Bioxcel Therapeutics Inc (BTAI)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BTAI Giù? Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Bioxcel Therapeutics Inc

Healthcare (1111)

203-643-8060

555 LONG WHARF DRIVE, NEW HAVEN, CT

Prossima data di guadagno

Ultimi documenti SEC

BTAI's Discussions on Twitter

Compare BTAI vs TAK, ZTS, HLN, TEVA, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BTAI Bioxcel Therapeutics Inc	1.58	33.68M	752.00K	-68.21M	-58.21M	-9.6977
TAK Takeda Pharmaceutical Co Adr	18.46	58.03B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	126.65	55.37B	9.40B	2.65B	2.24B	5.935
HLN Haleon Plc Adr	11.20	49.70B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	33.98	39.50B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	473.66	20.50B	3.13B	1.27B	1.12B	26.39

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-02-21	Downgrade	UBS	Buy → Neutral
2023-08-15	Downgrade	Mizuho	Buy → Neutral
2023-07-17	Downgrade	Guggenheim	Buy → Neutral
2023-03-10	Downgrade	Jefferies	Buy → Hold
2022-12-01	Aggiornamento	Goldman	Sell → Neutral
2022-07-07	Iniziato	Mizuho	Buy
2022-04-06	Reiterato	BofA Securities	Buy
2021-11-15	Downgrade	Goldman	Neutral → Sell
2021-04-09	Iniziato	Berenberg	Buy
2021-02-01	Iniziato	UBS	Buy
2020-10-30	Iniziato	Goldman	Buy
2020-09-02	Iniziato	Jefferies	Buy
2020-08-17	Reiterato	H.C. Wainwright	Buy
2020-07-08	Reiterato	H.C. Wainwright	Buy
2020-06-04	Iniziato	Guggenheim	Buy
2020-04-01	Iniziato	BofA/Merrill	Buy
2020-02-26	Reiterato	H.C. Wainwright	Buy
2020-01-08	Reiterato	H.C. Wainwright	Buy
2019-11-12	Iniziato	SunTrust	Buy

Mostra tutto

Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie

Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari

Bioxcel Therapeutics Inc (BTAI)

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Compare BTAI vs TAK, ZTS, HLN, TEVA, UTHR

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie

What earnings margins imply for BioXcel Therapeutics Inc. (BX20) stockJuly 2025 Levels & Daily Momentum Trading Reports - mfd.ru

Movement Recap: Is BioXcel Therapeutics Inc. benefiting from interest rate changes2025 Top Decliners & AI Driven Stock Movement Reports - mfd.ru

Bioxcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for Igalmi in the At-Home Setting - marketscreener.com

BioXcel Therapeutics (BTAI) Advances with Igalmi for At-Home Use - GuruFocus

BioXcel Highlights IGALMI At-Home Acute Agitation Opportunity - TipRanks

BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting - The Manila Times

BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI in the At-Home Setting - Bitget

BioXcel Therapeutics Completes Market Assessment for IGALMI - TradingView

86M at-home agitation episodes a year: IGALMI as potential option - Stock Titan

How cyclical is BioXcel Therapeutics Inc.’s revenue streamPortfolio Gains Report & High Accuracy Buy Signal Tips - mfd.ru

Aug Selloffs: What are the risks of holding BioXcel Therapeutics Inc.Weekly Volume Report & Consistent Growth Stock Picks - mfd.ru

BioXcel Therapeutics announces milestone and retention bonuses for key executives - Investing.com

BioXcel sets milestone bonuses amid pivotal IGALMI review - TipRanks

CEO Moves: What is GMFIWs 5 year growth outlookTrade Entry Report & Community Supported Trade Ideas - baoquankhu1.vn

Rate Hike: Is BioXcel Therapeutics Inc gaining market share2025 Key Highlights & Growth Focused Entry Reports - baoquankhu1.vn

Movement Recap: Is BioXcel Therapeutics Inc. stock a falling knife or bargain buyJuly 2025 Opening Moves & Stepwise Trade Signal Guides - mfd.ru

BioXcel Says Doctor Sent Fake Email About Alzheimer's Trial - Law360

BioXcel Therapeutics submits sNDA for at-home use of IGALMI By Investing.com - Investing.com South Africa

BioXcel Therapeutics (BTAI) Advances Igalmi's Reach with FDA Sub - GuruFocus

BioXcel Therapeutics submits application to expand IGALMI use for at-home treatment - Investing.com Nigeria

BioXcel seeks FDA approval for at-home IGALMI use - TipRanks

BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting - The Manila Times

BioXcel Therapeutics Submits Supplemental NDA To US FDA For IGALMI® At-Home Label Expansion - TradingView

BioXcel Therapeutics submits sNDA for at-home use of IGALMI - Investing.com

BioXcel Therapeutics Submits sNDA for IGALMI® At-Home Use - TradingView

What are the risks of holding BioXcel Therapeutics Inc.Weekly Trade Report & Capital Protection Trading Alerts - bollywoodhelpline.com

How BioXcel Therapeutics Inc. (BX20) stock moves on employment data2025 Fundamental Recap & Weekly Breakout Watchlists - bollywoodhelpline.com

Ag Plus, Inc. - Ag Plus, Inc.

Palmetto Grain Brokerage - Palmetto Grain Brokerage

1 Top Penny Stock to Watch Now - Yahoo Finance

Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com

BioXcel adds chief commercial officer as it prepares to expand agitation drug IGALMI’s reach - Hartford Business Journal

VIX Spike: Can BioXcel Therapeutics Inc. stock maintain growth trajectoryTrade Entry Report & Smart Swing Trading Alerts - Bộ Nội Vụ

BioXcel Therapeutics Appoints Mark Pavao as Interim Chief Commercial Officer - citybiz

Returns Recap: Is BioXcel Therapeutics Inc benefiting from interest rate changesJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn

BioXcel Therapeutics names interim CCO amid IGALMI expansion - TipRanks

BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting - The Manila Times

BioXcel Therapeutics Announces Interim Chief Commercial Officer - TradingView

Drugmaker taps veteran to pursue at-home treatment for bipolar agitation - Stock Titan

Published on: 2026-01-09 03:25:25 - Улправда

Oklahoma City NewsThe Oklahoman - FinancialContent

Trend Review: How institutional buying supports BioXcel Therapeutics Inc. stockJuly 2025 Spike Watch & Breakout Confirmation Trade Signals - Улправда

Will BioXcel Therapeutics Inc. stock attract ESG investorsQuarterly Portfolio Summary & Consistent Profit Alerts - ulpravda.ru

Is BioXcel Therapeutics Inc. (BX20) stock undervalued historicallyJuly 2025 Breakouts & Fast Moving Stock Trade Plans - Улправда

What insider trading reveals about BioXcel Therapeutics Inc. stockTrade Risk Assessment & Fast Entry Momentum Alerts - ulpravda.ru

How robust is BioXcel Therapeutics Inc. (BX20) stock financial positionMACD Histogram Signals & Maximize Returns With Insights - ulpravda.ru

BioXcel Seeks FDA Nod For At-Home Use Of IGALMI In Bipolar And Schizophrenia Agitation - Nasdaq

BioXcel plans FDA submission for at-home agitation treatment - Investing.com

BioXcel plans FDA submission for at-home agitation treatment By Investing.com - Investing.com Nigeria

BTAI FinancialsIncome Statement - Quiver Quantitative

BioXcel Therapeutics, Inc. Plans Supplemental NDA Submission for IGALMI® Approval for At-Home Use in Treating Agitation Associated with Bipolar Disorders and Schizophrenia - Quiver Quantitative

Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a BTAI